Skip to main navigation
Skip to main content
Skip to Footer

Navigate Novartis

Coronavirus

Global
- Novartis site directory

Our Company
Our Focus
Our Impact
Our Science
Careers

All News

Advanced Search Basic Search

From Date:

To Date:

Show:

All

Key Releases

Media Releases

Featured News

In the News

Stories

Statements

Pulse Updates

Filter By

Language:

En

Fr

De

2021

July

Key Release / Jul 21, 2021

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Media Release / Jul 20, 2021

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Media Release / Jul 14, 2021

Novartis announces NEJM publication of positive Phase III REACH3 data for Jakavi in chronic GvHD

June

Key Release / Jun 28, 2021

Novartis appoints Rob Kowalski as Chief People & Organization Officer

Media Release / Jun 25, 2021

Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer

Media Release / Jun 23, 2021

Positive survival data for Novartis investigational radioligand therapy 177Lu-PSMA-617 published in The New England Journal of Medicine

Media Release / Jun 23, 2021

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

Media Release / Jun 22, 2021

Kesimpta® (ofatumumab) data show long-term preservation of IgG/IgM levels and no increased risk of serious infections in people living with multiple sclerosis

Media Release / Jun 18, 2021

New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

Media Release / Jun 11, 2021

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Search Results Navigation

Current page 1 of 5
Page 2 of 5
Page 3 of 5
Page 4 of 5
Page 5 of 5
…
Next page
Last page

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Related Links

Stay Up-to-Date
We are inspiring our people
Malaria
Novartis SEC Filings

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

You are here

Home ›
Media

Novartis Global

Navigate Novartis
Contact Us
About Novartis
Our Portfolio
- Global Product Portfolio
- Global Clinical Pipeline
Careers
- Career Search

Connect with Novartis

twitter
linkedin
youtube
facebook
instagram

Novartis Site Directory

© 2021 Novartis AG

Terms of Use
Privacy
Contact Us
Site Map
Cookie Settings

This site is intended for a global audience.